LU90297I2 - Rivastigmine ses sels et dérivés pharmaceutiquement acceptables en particulier la rivastigmine sous forme d'hydrogénotartrate - Google Patents

Rivastigmine ses sels et dérivés pharmaceutiquement acceptables en particulier la rivastigmine sous forme d'hydrogénotartrate

Info

Publication number
LU90297I2
LU90297I2 LU90297C LU90297C LU90297I2 LU 90297 I2 LU90297 I2 LU 90297I2 LU 90297 C LU90297 C LU 90297C LU 90297 C LU90297 C LU 90297C LU 90297 I2 LU90297 I2 LU 90297I2
Authority
LU
Luxembourg
Prior art keywords
rivastigmine
derivatives
pharmaceutically acceptable
acceptable salts
hydrogen tartrate
Prior art date
Application number
LU90297C
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6322236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90297(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LU90297I2 publication Critical patent/LU90297I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
LU90297C 1987-03-04 1998-10-07 Rivastigmine ses sels et dérivés pharmaceutiquement acceptables en particulier la rivastigmine sous forme d'hydrogénotartrate LU90297I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3706914 1987-03-04

Publications (1)

Publication Number Publication Date
LU90297I2 true LU90297I2 (fr) 1998-12-07

Family

ID=6322236

Family Applications (2)

Application Number Title Priority Date Filing Date
LU87150A LU87150A1 (fr) 1987-03-04 1988-03-02 Nouveau carbamate de phenyle,sa preparation et son utilisation comme medicament
LU90297C LU90297I2 (fr) 1987-03-04 1998-10-07 Rivastigmine ses sels et dérivés pharmaceutiquement acceptables en particulier la rivastigmine sous forme d'hydrogénotartrate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU87150A LU87150A1 (fr) 1987-03-04 1988-03-02 Nouveau carbamate de phenyle,sa preparation et son utilisation comme medicament

Country Status (29)

Country Link
US (1) US5602176A (fr)
JP (3) JP2625478B2 (fr)
KR (1) KR0133686B1 (fr)
AT (1) AT394190B (fr)
AU (1) AU618949B2 (fr)
BE (1) BE1001467A3 (fr)
CA (1) CA1307003C (fr)
CH (1) CH675720A5 (fr)
CS (1) CS411091A3 (fr)
CY (1) CY1735A (fr)
DK (1) DK175762B1 (fr)
ES (1) ES2010527A6 (fr)
FI (1) FI89165C (fr)
FR (1) FR2611707B1 (fr)
GB (1) GB2203040C (fr)
GR (1) GR1000023B (fr)
HK (1) HK110093A (fr)
HU (1) HU201906B (fr)
IE (1) IE61714B1 (fr)
IL (1) IL85609A (fr)
IT (1) IT1219853B (fr)
LU (2) LU87150A1 (fr)
MY (1) MY103225A (fr)
NL (1) NL195004C (fr)
NZ (1) NZ223714A (fr)
PT (1) PT86875B (fr)
SA (1) SA93140384B1 (fr)
SE (1) SE8800731L (fr)
ZA (1) ZA881584B (fr)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
EP0755685A4 (fr) * 1994-04-15 2000-05-03 Meiji Seika Kaisha Composition medicinale destinee a traiter la dyskinesie tardive et utilisation de ladite composition
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
DK0966435T3 (da) 1996-12-18 2005-08-15 Teva Pharma Aminoindanderivater
JP4116085B2 (ja) * 1996-12-18 2008-07-09 テバ・ファーマシューティカル・インダストリーズ・リミテッド フェニルエチルアミン誘導体
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
IL141762A0 (en) 1998-10-01 2002-03-10 Novartis Ag New oral formulations
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
JP2002531502A (ja) * 1998-12-11 2002-09-24 デイビス、ボニー 視床下部−下垂体−生殖腺軸変調に於けるアセチルコリンエステラーゼ阻害剤の使用
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
CZ293014B6 (cs) * 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
MXPA04006900A (es) * 2002-10-24 2004-10-15 Merz Pharma Gmbh & Co Kgaa Politerapia que utiliza derivados de 1-aminociclohexano e inhibidores de acetilcolinesterasa.
WO2004071431A2 (fr) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Composition et methode de traitement de troubles neurodegeneratifs
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
JP2007528857A (ja) * 2003-07-11 2007-10-18 ミリアド ジェネティクス， インコーポレイテッド アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
CN1898201A (zh) * 2003-10-21 2007-01-17 森蒂有限公司 可抑制胆碱酯酶和释放药理学活性试剂的氨基甲酸酯
GB2409453A (en) 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
MXPA06012165A (es) * 2004-04-29 2007-01-17 Keystone Retaining Wall System Chapas para muros, muros de contencion y similares.
US20080045500A1 (en) * 2004-07-01 2008-02-21 Eisai R&D Management Co., Ltd. Nerve Regeneration Stimulator
WO2006020852A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
WO2006020853A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
WO2006020850A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
EP1856036B1 (fr) * 2004-11-08 2016-12-14 Emcure Pharmaceuticals Limited Procede efficace de preparation de (s)-3-[(1-dimethyl amino)ethyl]-phenyl-n-ethyl-n-methyl-carbamate
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
JP5116679B2 (ja) 2005-09-15 2013-01-09 株式会社ソニー・コンピュータエンタテインメント 強度のコンピュータ画像および音声処理、ならびにコンピュータプログラムとインタフェースするための入力装置
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
ES2632638T3 (es) * 2005-12-09 2017-09-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Ladostigilo de baja dosis para el tratamiento de la deficiencia cognitiva
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) * 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
EP2054373B1 (fr) * 2006-08-17 2010-06-30 Alembic Limited Procédé pour la préparation de rivastigmine amélioré
WO2008037433A1 (fr) 2006-09-29 2008-04-03 Synthon B.V. Procédé de fabrication de carbamates d'aminoalkylphényle et intermédiaires de cette fabrication
WO2008051599A2 (fr) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Procédés et combinaison de thérapies pour le traitement de la maladie d'alzheimer
EP1942100A1 (fr) * 2007-01-04 2008-07-09 Krka Tovarna Zdravil, D.D., Novo Mesto Formes amorphes et cristallines dýhydrogénotartrate de rivastigmine
US8101782B2 (en) * 2007-02-02 2012-01-24 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
EP1980552A3 (fr) 2007-04-10 2008-10-29 Dr. Reddy's Laboratories Ltd. Processus pour la préparation de rivastigmine ou sel correspondant
CN101707952B (zh) * 2007-04-16 2012-08-29 上海特化医药科技有限公司 一种制备利伐斯的明的方法及其中间体
US7884121B2 (en) * 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
AU2008276459A1 (en) * 2007-07-18 2009-01-22 Colucid Pharmaceuticals, Inc. Methods for promoting wakefulness
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
US20090082436A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched rivastigmine
US8324429B2 (en) * 2008-01-10 2012-12-04 Shanghai Institute Of Pharmaceutical Industry Preparation method of rivastigmine, its intermediates and preparation method of the intermediates
US8420846B2 (en) 2008-08-25 2013-04-16 Jubilant Life Sciences Limited Process for producing (S)-3-[(1-dimethylamino)ethyl] phenyl-N-ethyl-N-methyl-carbamate via novel intermediates
US20100087768A1 (en) * 2008-10-02 2010-04-08 Forlano Paula Transdermal drug delivery system for liquid active ingredient
GB0823554D0 (en) * 2008-12-24 2009-01-28 Novartis Ag Process for the preparation of optically active compounds using transfer hydrogenation
CN101823970B (zh) * 2009-03-03 2013-05-08 江苏恩华药业股份有限公司 卡巴拉汀及其中间体的合成方法
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
BR112012017168B1 (pt) 2009-12-22 2022-03-15 Luye Pharma Ag Sistemas terapêuticos transdérmicos, seu processo de preparação, e usos de um polímero ou copolímero
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
CA2789014C (fr) 2010-02-09 2019-01-15 Michela Gallagher Procedes et compositions pour ameliorer la fonction cognitive
SG10201505374TA (en) 2010-03-29 2015-08-28 Novartis Ag Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
WO2011151669A1 (fr) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Procédé de production d'un isomère énantiomériquement enrichi d'un dérivé du 3-(1-aminoéthyle) phényle et son utilisation pour produire de la rivastigmine ou son sel pharmaceutiquement acceptable
WO2011151359A1 (fr) 2010-06-02 2011-12-08 Noscira, S.A. Traitement combiné comprenant un inhibiteur de la cholinestérase et un dérivé de thiadiazolidinedione
HUE038434T2 (hu) 2010-06-17 2018-10-29 Codexis Inc Biokatalizátorok és módszerek (S)-3(1-aminoetil)-fenol szintéziséhez
WO2012068161A1 (fr) 2010-11-15 2012-05-24 Agenebio, Inc. Dérivés de pyridazine, compositions et méthodes de traitement d'une déficience cognitive
ES2545094T3 (es) 2010-12-14 2015-09-08 Acino Ag Sistema terapéutico transdérmico para la administración de un principio activo
CN102786441B (zh) 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
JP6017543B2 (ja) 2011-05-20 2016-11-02 エスケー ケミカルズ カンパニー, リミテッドSk Chemicals Co., Ltd. リバスティグミン含有パッチ
AR082640A1 (es) * 2011-08-25 2012-12-19 Amarin Technologies S A Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
EP2752188B1 (fr) 2011-08-31 2020-05-06 Toyo Ink Sc Holdings Co., Ltd. Timbre transdermique
CN103073456B (zh) * 2011-10-26 2014-03-19 连云港润众制药有限公司 重酒石酸卡巴拉汀中间体的制备方法
EP2594261A1 (fr) 2011-11-18 2013-05-22 Labtec GmbH Composition pour administration transdermique de rivastigmine
WO2013142339A1 (fr) 2012-03-23 2013-09-26 Novartis Ag Système thérapeutique transdermique et procédé associé
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
KR20140038237A (ko) 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CN103896787A (zh) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 一种卡巴拉汀前体[1-(3-甲氧基苯基)乙基]二甲胺的制备方法
WO2014111790A2 (fr) 2013-01-15 2014-07-24 Zydus Technologies Limited Système d'administration de médicament pharmaceutique transdermique stable comprenant de la rivastigmine
WO2014144663A1 (fr) 2013-03-15 2014-09-18 The Johns Hopkins University Procédés et compositions pour améliorer la fonction cognitive
CA2904767C (fr) 2013-03-15 2022-06-21 Agenebio, Inc. Procedes et compositions pour ameliorer la fonction cognitive
CN103319374B (zh) * 2013-06-09 2015-04-22 无锡佰翱得生物科学有限公司 一种(s)-卡巴拉汀的不对称合成方法
AU2014307803A1 (en) 2013-08-16 2016-03-10 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
EP3083569B1 (fr) 2013-12-20 2022-01-26 Agenebio, Inc. Dérivés de benzodiazépine, compositions et procédés de traitement de la déficience cognitive
WO2016191288A1 (fr) 2015-05-22 2016-12-01 Agenebio, Inc. Compositions pharmaceutiques de lévétiracétam à libération prolongée
CN108026107B (zh) 2015-06-19 2021-07-30 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CA3104478A1 (fr) 2018-06-19 2019-12-26 Agenebio, Inc. Derives de benzodiazepine, compositions, et methodes de traitement de deficience cognitive
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성
WO2024039886A1 (fr) 2022-08-19 2024-02-22 Agenebio, Inc. Dérivés de benzoazépine, compositions et méthodes de traitement de déficience cognitive

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469700A (en) * 1981-06-19 1984-09-04 Lowell M. Somers Benzoylecgonine or benzoylnorecgonine as active agents for the treatment of rheumatoid arthritis
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.

Also Published As

Publication number Publication date
US5602176A (en) 1997-02-11
CH675720A5 (fr) 1990-10-31
IL85609A0 (en) 1988-08-31
GB2203040C (en) 2014-07-30
KR880011088A (ko) 1988-10-26
SE8800731A0 (sv) 1988-09-05
NL195004C (nl) 2003-11-04
IT1219853B (it) 1990-05-24
JP2625478B2 (ja) 1997-07-02
FR2611707B1 (fr) 1990-04-20
PT86875A (pt) 1988-04-01
HU201906B (en) 1991-01-28
KR0133686B1 (ko) 1998-04-21
NL195004B (nl) 2003-07-01
NL8800436A (nl) 1988-10-03
IE61714B1 (en) 1994-11-30
IT8847693A0 (it) 1988-03-04
AU1255488A (en) 1988-09-08
HK110093A (en) 1993-10-29
JPH09165362A (ja) 1997-06-24
JP2859225B2 (ja) 1999-02-17
FI880972A (fi) 1988-09-05
LU87150A1 (fr) 1988-11-17
DK112588D0 (da) 1988-03-02
JPS63238054A (ja) 1988-10-04
HUT49325A (en) 1989-09-28
GB2203040B (en) 1990-10-24
FI880972A0 (fi) 1988-03-02
BE1001467A3 (fr) 1989-11-07
DK175762B1 (da) 2005-02-14
CY1735A (en) 1994-06-03
ZA881584B (en) 1989-11-29
CA1307003C (fr) 1992-09-01
SE8800731L (sv) 1988-09-05
SA93140384B1 (ar) 2006-04-04
CS411091A3 (en) 1992-12-16
IE880583L (en) 1988-09-04
FR2611707A1 (fr) 1988-09-09
ATA55188A (de) 1991-08-15
NZ223714A (en) 1994-05-26
MY103225A (en) 1993-05-29
SE8800731D0 (sv) 1988-03-02
GB2203040A (en) 1988-10-12
GB8804888D0 (en) 1988-03-30
IL85609A (en) 1992-07-15
PT86875B (pt) 1992-05-29
FI89165C (fi) 1993-08-25
GR880100125A (en) 1989-01-31
AU618949B2 (en) 1992-01-16
GR1000023B (el) 1990-01-31
FI89165B (fi) 1993-05-14
ES2010527A6 (es) 1989-11-16
DK112588A (da) 1988-09-05
JPH09118617A (ja) 1997-05-06
AT394190B (de) 1992-02-10

Similar Documents

Publication Publication Date Title
LU90297I2 (fr) Rivastigmine ses sels et dérivés pharmaceutiquement acceptables en particulier la rivastigmine sous forme d&#39;hydrogénotartrate
LU91131I2 (fr) Duloxétine et ses sels d&#39;addition acides pharmaceutiquement acceptables, et en particulier, chlorhydrate de duloxétine.
LU90866I2 (fr) Hydrochlorure de sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d&#39;hydrochlorurede sibutramine
LU90098I2 (fr) Ropinirole facultativement sous forme de sels pharmaceutiquement acceptables et de préférence le sel hydrochlorique
LU91452I2 (fr) &#34;Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)&#34;
CA2014889A1 (fr) Composes pharmaceutiques
LU91599I2 (fr) Lasofoxifene, optionnellement sous forme d&#39;un sel d&#39;addition acide, d&#39;un N-oxyde, d&#39;unester ou d&#39;un sel d&#39;ammonium quaternaire, non toxiques et pharmacologiquement acceptables, y compris le sel tartrate (FABLYN - lasofoxifene)
LU91306I2 (fr) Mitratapide, optionnellement sous forme d&#39;un sel d&#39;addition acide pharmaceutiquement acceptable (YARVITAN)
LU88809I2 (fr) Lamivudine facultativement sous la forme d&#39;un sel pharmaceutiquement acceptable
GR870525B (en) Improvements in pharmaceutically acceptable salts
LU90829I2 (fr) Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables
PT84041A (en) Process for the preparation of optically pure s-(-)-1-propyl-2:,6:-pipecoloxylidide hydrochloride monohydrate and of pharmaceutical compositions containing the same
IL87339A0 (en) 2-((4-piperidyl)methyl)-1,2,3-4-tetrahydroisoquinoline derivatives,their preparation and their application in therapy
HUT41784A (en) Process for producing 1,8-naphtiridine derivatives and pharmaceutical compositions containing them as active agents
MY103210A (en) Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds.
BG101884A (en) Salts of the clavulanic acid
CS621687A2 (en) Metod of 2,3,4,5,6,7-hexahydro-2,7-methano-1,5-benzoxazonine&#39;s or 1,4-benzoxazonine&#39;s pharmacologically active,pain alleviating derivatives production
HUT41233A (en) Insekticide, acaricide and nematocide compositions containing new benzoyl-phenyl-urea derivatives and process for producing the active agents
NZ224812A (en) Derivatives of 2&#39;,3&#39;-dideoxycytidine and pharmaceutical compositions
AU1621788A (en) Pharmacologically active cholinergic compositions, and methods for making same and use thereof in treating disease
FI894813A0 (fi) Menetelmä terapeuttisesti aktiivisten 2-metoksikarbonyylisubstituoitujen N,N&#39;-di(trimetoksibentsoyyli)piperatsiinijohdannaisten valmistamiseksi
FR2607676B1 (fr) Procede d&#39;obtention de compositions alimentaires sous forme de mousse
EP0275104A3 (en) Process for preparing 2,3-dihydro-1h-imidazolylalkoxyindene derivatives and pharmaceutically acceptable salts
MX9703839A (es) Soluciones intravenosas de lubeluzol.
PT75838A (en) Process for the preparation of 2,3,4,5-tetrhydro-1h-3benzoaze phines n-substituted and their pharmaceutically acceptable salts with alpha 2 antagonism